Capd/dpca 3

Incompatibilities

Compatible with heparin. Increases the arrhythmogenicity of digitalis (may exacerbate digitalis intoxication).

Pharmaceutical form

Solution for peritoneal dialysis

Undesirable effects

Abdominal pain, bleeding, peritonitis, intestinal obstruction, water-electrolyte balance disorders, hypo - or hypervolemia, hyper-or hypotension, balance disorder, muscle cramps, infection around the catheter in the subcutaneous tunnel.

Therapeutic indications

Acute and chronic renal failure, fluid retention in the body, electrolyte balance disorders, drug intoxication, correction of hyperkalemia, prevention of hypokalemia.

Pharmacotherapeutic group

  • Detoxifying agents, including antidotes, in combinations

Name of the medicinal product

CAPD/DPCA 3

Special precautions for storage

At a temperature not exceeding 25 °C (do not freeze).

Keep out of reach of children.

The shelf life of the drug CAPD/dpca of 32 года.

Do not use after the expiration date indicated on the package.

Nosological classification (ICD-10)

  • N17 Acute renal failure
  • N18. 0 End-stage renal disease

Qualitative and quantitative composition

Peritoneal Dialysis Solutions

Dosage (Posology) and method of administration

Intraperitoneal. The frequency of dialysis sessions, the volume of the solution per session, the duration of the solution in the abdominal cavity and the duration of dialysis are determined individually. On average, it is recommended to conduct from 3 to 5 dialysis sessions per day using from 1500 to 2000 ml of solution per session.

ATC - Anatomical and therapeutic chemical classification

B05D Solutions for peritoneal dialysis